ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2107

Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture

(2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1922

Exploration of patient and clinician perspectives on rehabilitation in contemporary rheumatology care for rheumatoid arthritis: A qualitative study

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 1905

Exploring the Association Between Environmental Quality Index and Rheumatoid Arthritis Mortality in the United States

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2008

Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2226

Factors Associated with Contraceptive Counseling by Rheumatologists for Reproductive-Aged Female Patients Prescribed Teratogenic Medications

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

10:30AM-12:30PM: Abstract Number: 2378

Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2563

Factors Associated With Medication Use in the Preconception and Perinatal Period Among Women With Autoimmune Disorders: A Systematic Review

(2547–2566) ARP Posters I

10:30AM-12:30PM: Abstract Number: 2138

Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2380

Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2224

Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

10:30AM-12:30PM: Abstract Number: 1875

Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy

(1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 2075

Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1919

Financial insecurity and discrimination are associated with patient-reported quality of life in patients with SLE

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 1850

First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses

(1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2080

Foot laterality does not modify outcome of knee and/or hip osteoarthritis

(2079–2105) Osteoarthritis – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].